QINGDAO, China, Feb. 19, 2025 /PRNewswire/ -- Hisense, a global leader in consumer electronics and home appliances, is once again demonstrating its dominance by securing the top position globally in Laser TV. According to data from the international market research institute Omdia, Hisense's laser TV achieved a 65.8% global market share in 2024, meaning that for every three laser TVs sold, nearly two are from Hisense. This also marks six consecutive years as the world's leading Laser TV shipment provider.
As one of the earliest entrants in the laser display market, Hisense has evolved its offerings — from single-color to triple-color laser systems, from 4K to 8K resolution, and from rollable to foldable screens — solidifying its leadership in the ultra-large screen TV segment. In 2024, Hisense recorded triple-digit year-on-year growth in key markets such as the UK, Italy, Spain, and Poland, while also posting increases of over 70% in France, Australia, and Germany.
Further establishing its leadership in the laser display industry, the Hisense PX3-PRO TriChroma Laser Projector secured the top spot at the 2024 Prestigious Projector Showdown. This prestigious event, which evaluates ultra short throw (UST) projectors, recognized the PX3-PRO for its superior performance in color accuracy, contrast, and sharpness, solidifying Hisense's position as a pioneer in the field. With groundbreaking features like a 3,000:1 native contrast ratio, 3,000 ANSI lumens brightness, and TriChromaâ„¢ triple laser technology, the PX3-PRO sets new standards in home entertainment.
Hisense's Laser TV leads in eye care with TÜV Rheinland Low Blue Light and Flicker-Free certifications, while its Laser TV PL1 earns ISO 14067 carbon footprint verification by TÜV Rheinland.
Hisense's relentless commitment to innovation and quality not only sustains its global leadership but also drives industry standards in ultra-large screen technology. With breakthrough advancements and impressive international growth, Hisense is poised to remain a dominant force in the evolving world of home entertainment.
About Hisense
Hisense is a leading global home appliance and consumer electronics brand. According to Omdia, Hisense has ranked No. 2 globally in total TV shipments from 2022 to 2024, and No. 1 in 100''+ TVs segment from 2023 to 2024. The company has rapidly expanded to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Hisense Laser TV Maintains Global No.1 Position for Six Years
HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.
Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.
To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).
Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.
Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.
The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.
Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.
This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.
These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.
Media Contact:
Chi Zhang
media@westlake.edu.cn
+86-15659837873
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform
